Improved determination of the bisphosphonate pamidronate disodium in plasma and urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection.
An improved method for the determination of 1-hydroxy-3-aminopropylidene-1,1-bisphosphonate (pamidronate) in human urine and plasma is described. The procedure is based on a co-precipitation of the bisphosphonates (pamidronate and 6-amino-1-hydroxypentilidene-bisphosphonate, used as internal standard) with calcium phosphate. After centrifugation the precipitate is redissolved in hydrochloric acid, followed by a second precipitation. Then the bisphosphonates are dissolved in ethylenediaminetetraacetic acid, derivatized with fluorescamine, and separated by high-performance liquid chromatography. Using fluorescence detection, the limit of quantitation for pamidronate was 0.8 mumol/l in plasma and 0.7 mumol/l in urine.
Flesch
G
G
Research and Development, Pharmaceuticals Division, Ciba-Geigy Limited, Basle, Switzerland.
Tominaga
N
N
Degen
P
P
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004164:Diphosphonates / Q000008:administration & dosage / Q000097:blood* / Q000652:urine*; D005450:Fluorescamine; D005453:Fluorescence; D006801:Humans; D007262:Infusions, Intravenous; D000077268:Pamidronate
D004164:Diphosphonates; D005450:Fluorescamine; D000077268:Pamidronate